Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma

Sorafenib is one of the few effective first-line drugs approved for the treatment of advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common among individuals with HCC. Recent evidence indicated that the anticancer activity of sorafenib mainly relies on the ind...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Xiaoju Li, Qianqian Yu, Runze Zhao, Xinyan Guo, Chenlin Liu, Kuo Zhang, Wangqian Zhang, Jinghan Liu, Jinzheng Yu, Shuning Wang, Qiang Hao, Weina Li, Wei Zhang, Meng Li, Yingqi Zhang, Cun Zhang, Yuan Gao
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-06-01
Saila:	Frontiers in Oncology
Gaiak:	hepatocellular carcinoma resistance sorafenib engineered exosome ferroptosis
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2022.898156/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!